Murchinson Ltd. Acquires 8,889 Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

Murchinson Ltd. boosted its position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) by 0.5% in the third quarter, Holdings Channel.com reports. The firm owned 1,708,879 shares of the biotechnology company’s stock after buying an additional 8,889 shares during the quarter. Oramed Pharmaceuticals comprises approximately 1.1% of Murchinson Ltd.’s investment portfolio, making the stock its 15th largest position. Murchinson Ltd.’s holdings in Oramed Pharmaceuticals were worth $4,170,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the business. BML Capital Management LLC boosted its stake in Oramed Pharmaceuticals by 62.1% in the 3rd quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock worth $5,334,000 after purchasing an additional 837,153 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Oramed Pharmaceuticals by 89.0% in the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after buying an additional 108,700 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Oramed Pharmaceuticals during the third quarter valued at approximately $272,000. Dimensional Fund Advisors LP boosted its stake in Oramed Pharmaceuticals by 52.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 10,774 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Oramed Pharmaceuticals in the 1st quarter worth $68,000. Institutional investors own 12.73% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on ORMP. HC Wainwright reaffirmed a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th. StockNews.com downgraded shares of Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday.

Oramed Pharmaceuticals Price Performance

Shares of NASDAQ:ORMP opened at $2.46 on Wednesday. The stock has a market capitalization of $99.16 million, a PE ratio of 22.36 and a beta of 1.70. The firm’s 50 day moving average price is $2.36 and its 200-day moving average price is $2.38. Oramed Pharmaceuticals Inc. has a twelve month low of $2.00 and a twelve month high of $3.67.

Oramed Pharmaceuticals Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.